By The Registry Staff Codexis Inc., a Redwood City-based company (NASDAQ: CDXS), has announced significant changes to its operations and strategic focus. The company plans to discontinue all preclinical discovery work in gene therapy and other biotherapeutics. This decision will lead to a consolidation effort, resulting in a reduction of about 25 percent of its […]
Thank you for your interest in The Registry. If you'd like to read further, you must Subscribe or Log In below to read the rest of this content.
Signup for news and special announcements!
You have successfully joined our subscriber list.
A New York investment group tied to life science specialist Outshine Properties...
ByThe RegistryOctober 5, 2026A joint analysis by recruiting platform Juicebox and Newmark Research finds San...
ByThe RegistryOctober 5, 2026Shops at Foster Square, a 2017-vintage Foster City retail center anchored by...
ByThe RegistryOctober 5, 2026Gap Inc. is turning parts of its waterfront headquarters at 2 Folsom...
ByThe RegistryOctober 5, 2026